DARAPLADIB

Search structure
Synonyms:
Status: Phase 3
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: UI1U1MYH09

Structure
InChI Key WDPFJWLDPVQCAJ-UHFFFAOYSA-N
Smile CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2
InChI
InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C36H38F4N4O2S
Molecular Weight 666.79
AlogP 7.22
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 13.0
Polar Surface Area 58.44
Molecular species NEUTRAL
Aromatic Rings 4.0
Heavy Atoms 47.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR LDL-associated phospholipase A2 inhibitor PubMed
Primary Target
PLA2-G7
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6
- 26000 - - -
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- 27000 - - -
Enzyme Hydrolase
- 0-35 50 0 59-100

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Atherosclerosis 3 D050197 ClinicalTrials
Acute Coronary Syndrome 3 D054058 ClinicalTrials
Diabetic Retinopathy 2 D003930 ClinicalTrials

Related Entries

Scaffolds

Cross References

Resources Reference
CAS NUMBER 356057-34-6
ChEMBL CHEMBL204021
DrugBank DB06311
EPA CompTox DTXSID70189073
FDA SRS UI1U1MYH09
Guide to Pharmacology 6696
PDB 5HV
PharmGKB PA165884699
PubChem 9939609
SureChEMBL SCHEMBL2742709
ZINC ZINC000003842798
CONTENTS